Adcirca Patent Expiration

Adcirca is a drug owned by Eli Lilly Co. It is protected by 6 US drug patents filed from 2013 to 2018 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 19, 2021. Details of Adcirca's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6821975

(Pediatric)

Beta-carboline drug products
May, 2021

(3 years ago)

Expired
US6821975 Beta-carboline drug products
Nov, 2020

(3 years ago)

Expired
US7182958

(Pediatric)

β-carboline pharmaceutical compositions
Oct, 2020

(4 years ago)

Expired
US7182958 β-carboline pharmaceutical compositions
Apr, 2020

(4 years ago)

Expired
US5859006

(Pediatric)

Tetracyclic derivatives; process of preparation and use
May, 2018

(6 years ago)

Expired
US5859006 Tetracyclic derivatives; process of preparation and use
Nov, 2017

(6 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Adcirca's patents.

Given below is the list of recent legal activities going on the following patents of Adcirca.

Activity Date Patent Number
Patent litigations
Review Certificate Mailed 27 Jun, 2019 US6821975 (Litigated)
Review Certificate Mailed 26 Jun, 2019 US7182958 (Litigated)
Review Certificate 12 Jun, 2019 US6821975 (Litigated)
Review Certificate 12 Jun, 2019 US7182958 (Litigated)
Payment of Maintenance Fee, 12th Year, Large Entity 16 Jul, 2018 US7182958 (Litigated)
Termination or Final Written Decision 03 Aug, 2016 US6821975 (Litigated)
Termination or Final Written Decision 03 Aug, 2016 US7182958 (Litigated)
Request for Trial Granted 04 Aug, 2015 US7182958 (Litigated)
Petition Requesting Trial 13 Jan, 2015 US6821975 (Litigated)
Petition Requesting Trial 13 Jan, 2015 US7182958 (Litigated)


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Adcirca and ongoing litigations to help you estimate the early arrival of Adcirca generic.

Adcirca's Litigations

Adcirca been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 13, 2015, against patent number US7182958. The petitioner Actelion Pharmaceuticals Ltd, challenged the validity of this patent, with ICOS Corporation as the respondent. Click below to track the latest information on how companies are challenging Adcirca's patents.

Last updated on November 5, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6821975 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd
US7182958 January, 2015 FWD Entered
(03 Aug, 2016)
ICOS Corporation Actelion Pharmaceuticals Ltd


FDA has granted some exclusivities to Adcirca. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Adcirca, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Adcirca.

Exclusivity Information

Adcirca holds 2 exclusivities. All of its exclusivities have expired in 2016. Details of Adcirca's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 22, 2012
Orphan Drug Exclusivity(ODE) May 22, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Adcirca is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Adcirca's family patents as well as insights into ongoing legal events on those patents.

Adcirca's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Adcirca's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 19, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Adcirca Generic API suppliers:

Tadalafil is the generic name for the brand Adcirca. 29 different companies have already filed for the generic of Adcirca, with Macleods Pharms Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Adcirca's generic

How can I launch a generic of Adcirca before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Adcirca's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Adcirca's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Adcirca -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
20 mg 15 Oct, 2009 1 03 Aug, 2018 26 Apr, 2020 Eligible

Alternative Brands for Adcirca

Adcirca which is used for treating pulmonary hypertension., has several other brand drugs using the same active ingredient (Tadalafil). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Actelion
Opsynvi
Cmp Dev Llc
Tadliq
Lilly
Cialis


Apart from brand drugs containing the same ingredient, some generics have also been filed for Tadalafil, Adcirca's active ingredient. Check the complete list of approved generic manufacturers for Adcirca





About Adcirca

Adcirca is a drug owned by Eli Lilly Co. It is used for treating pulmonary hypertension. Adcirca uses Tadalafil as an active ingredient. Adcirca was launched by Eli Lilly Co in 2009.

Approval Date:

Adcirca was approved by FDA for market use on 22 May, 2009.

Active Ingredient:

Adcirca uses Tadalafil as the active ingredient. Check out other Drugs and Companies using Tadalafil ingredient

Treatment:

Adcirca is used for treating pulmonary hypertension.

Dosage:

Adcirca is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG TABLET Prescription ORAL